SLTE-1009 — Initial data
Mid 2027
The program has received clearance to enter Phase 1 clinical trials in Australia and initial pharmacokinetic and safety data is anticipated mid-year 2027.Source filing
FULC biotech catalysts & pipeline
FULCRUM THERAPEUTICS INC · Data as of 2026-09-08